Get the Stockscreener App
8.05
0.25%
-0.02
Vigil Neuroscience Inc stock is traded at $8.05, with a volume of 431.65K.
It is down -0.25% in the last 24 hours and up +1.51% over the past month.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
See More
Previous Close:
$8.07
Open:
$8.07
24h Volume:
431.65K
Relative Volume:
0.31
Market Cap:
$383.88M
Revenue:
-
Net Income/Loss:
$-82.60M
P/E Ratio:
-3.9078
EPS:
-2.06
Net Cash Flow:
$-48.61M
1W Performance:
-0.37%
1M Performance:
+1.51%
6M Performance:
+265.91%
1Y Performance:
+89.41%
1-Day Range:
$8.05
$8.08
1-Week Range:
$8.05
$8.09
52-Week Range:
$1.312
$8.10
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Name
Vigil Neuroscience Inc
Sector
Industry
Phone
857-254-4445
Address
100 FORGE ROAD, WATERTOWN
Compare VIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
8.05 | 376.17M | 0 | -82.60M | -48.61M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Initiated | William Blair | Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-18-23 | Initiated | JMP Securities | Mkt Outperform |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Sep-16-22 | Initiated | Wedbush | Outperform |
| Aug-29-22 | Initiated | H.C. Wainwright | Buy |
| Feb-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Initiated | Jefferies | Buy |
| Feb-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-01-22 | Initiated | Stifel | Buy |
View All
Vigil Neuroscience Inc Stock (VIGL) Latest News
What drives Vigil Neuroscience Inc. stock priceFree Capital Growth Strategies - Autocar Professional
Does Vigil Neuroscience Inc. stock pay reliable dividendsFree Stock Market Forecast Reports - jammulinksnews.com
Is Vigil Neuroscience Inc. a good long term investmentTremendous gains - PrintWeekIndia
How high can Vigil Neuroscience Inc. stock price go in 2025Exceptional trading performance - jammulinksnews.com
What analysts say about Vigil Neuroscience Inc. stockFree Investment Community - jammulinksnews.com
Vigil Neuroscience Inc. Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com
Vigil Neuroscience Awaits HSR Expiration for Sanofi Merger - The Globe and Mail
Vigil Neuroscience merger with Sanofi clears U.S. antitrust waiting period By Investing.com - Investing.com Nigeria
Vigil Neuroscience merger with Sanofi clears U.S. antitrust waiting period - Investing.com Australia
How Vigil Neuroscience Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
Why Vigil Neuroscience Inc. stock attracts strong analyst attention10x Potential Stocks - Newser
What makes Vigil Neuroscience Inc. stock price move sharplyFree VIP Investment Strategies - Newser
Brokerages Set Vigil Neuroscience, Inc. (NASDAQ:VIGL) PT at $10.80 - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, CHTR, VIGL on Behalf of Shareholders - MarketScreener
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc.VIGL - The Globe and Mail
TREM2 agonists reported in Vigil Neuroscience patents - BioWorld MedTech
Vigil Neuroscience (NASDAQ:VIGL) Stock Price Up 0.4% – Here’s What Happened - Defense World
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: TASK, VIGL, STRM, and CHTR - The Malaysian Reserve
Vigil Neuroscience Announces Special Meeting for Sanofi Merger Vote - TipRanks
Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - Nasdaq
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTCCRKN), Elevation Oncology, Inc. (NasdaqELEV), Sitio Royalties Corp. (NYSESTR), Vigil Neuroscience, Inc. (NasdaqV - TradingView
Vigil Neuroscience Inc Stock (VIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.32%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):